#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Hereditary angioedema with C1 esterase inhibitor deficiency Anal cancer recurrent Epstein-Barr virus associated lymphoproliferative disorder Ataxia telangiectasia Transient ischaemic attack Glioma Adenoid cystic carcinoma Hypereosinophilic syndrome Essential thrombocythaemia Homocystinuria Granulomatosis with polyangiitis Leiomyosarcoma recurrent IPEX syndrome Cognitive disorder Inclusion body myositis More trials…

    Learn about Rare Diseases

    Leukoencephalopathy – Treatment Wiskott-Aldrich syndrome – Treatment Rhabdoid tumour – Life with Disease Rhabdomyosarcoma recurrent – Life with Disease Primary hyperoxaluria – Trials in Disease Ewing’s sarcoma metastatic – Trials in Disease Lysosomal storage disorder – Trials in Disease Lymphangioma – Basic Information Hepatic angiosarcoma – Diagnostics Fabry’s disease – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    L-Histidine Hydrochloride Ecubectedin Omaveloxolone Forimtamig Ribonucleic Acid K30 X-396 Sufentanil Citrate Camonsertib Solifenacin Succinate Esketamine Interferon Beta-1A GSK5460025A Exl01 D5-Ethyl-Beta-D-Glucuronide YL201 Almagate Nivolumab Tebentafusp F44/10 Sym024 More therapies…

    Learn about Your Condition

    Aplastic anaemia Peritoneal abscess Von Hippel-Lindau disease Gestational diabetes Inflammation Ventricular tachycardia Hypotonia Bone marrow disorder Infective uveitis Abdominal infection Persistent depressive disorder Hereditary optic atrophy Meningorrhagia Crigler-Najjar syndrome Insulin resistance More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Prostate cancer metastatic

  • Phase I/II Study of AZD6621 Safety and Efficacy in Adult Men with Metastatic Prostate Cancer

    Recruiting

    2 1 1
    Investigated Diseases:
    • Prostate cancer metastatic
    Belgium Italy The Netherlands Poland Spain

  • A study to evaluate the safety and effectiveness of AZD9750 and saruparib in patients with metastatic prostate cancer

    Recruiting

    2 1 1
    Investigated Diseases:
    • Prostate cancer metastatic
    Investigated Drugs:
    • Saruparib
    The Netherlands Spain

  • A study evaluating the efficacy and safety of inavolisib and enzalutamide in patients with metastatic castration-resistant prostate cancer

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Inavolisib
    • Abiraterone
    • Enzalutamide
    France Germany Italy Spain

  • A study testing the safety and effectiveness of AZD0516 alone and with other cancer drugs in adults with metastatic prostate cancer

    Recruiting

    2 1 1
    Investigated Diseases:
    • Prostate cancer metastatic
    Investigated Drugs:
    • 6-Fluoro-5-[4-[(5-Fluoro-2-Methyl-3-Oxo-4H-Quinoxalin-6-Yl)Methyl]Piperazin-1-Yl]-N-Methylpyridine-2-Carboxamide
    • AZD0516
    Italy Poland Spain

  • Study of ifinatamab deruxtecan alone or in combination with other treatments for patients with metastatic castration-resistant prostate cancer

    Recruiting

    1 1 1 1
    Investigated Diseases:
    • Prostate cancer metastatic
    Investigated Drugs:
    • Fludrocortisone Acetate
    • Opevesostat Tosilate
    • Abiraterone
    France Germany Ireland Italy The Netherlands Poland +1

  • Safety Study of Tumor-Infiltrating Lymphocyte (TIL) Therapy for Patients with Metastatic Colorectal or Prostate Cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Prostate cancer metastatic
    • Colorectal cancer metastatic
    • Prostate cancer
    Investigated Drugs:
    • Aldesleukin
    • Mesna
    • Cyclophosphamide Monohydrate
    Germany
1 2 3 … 8
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!